The World Health Organization announced that Crown Vaccine, a Chinese pharmaceutical dealer Kangxino Bio, was included in the emergency use list (EUL) and became the 11th of these types of vaccines.
According to Bloomberg, the WHO said on Thursday that the consulting team determined that the vaccine of the Chinese company complied with WHO standards, and its benefits were far greater than risks.
WHO said that Kwaisa's prevention rate for symptomatic crown disease was 64%, and the severe prevention rate was 92%.Strategic consulting experts formed adults to use 0.5 ml of single -agent Kwaisa vaccine.
